Camurus' Oczyesa® Secures Marketing Approval in the EU for Acromegaly Camurus announces that Oczyesa®, a subcutaneous octreotide depot, has received marketing authorization in the EU for treating acromegaly.

Camurus' Oczyesa® Secures Marketing Approval in the EU for Acromegaly #Sweden #Lund #Camurus #Oczyesa #Acromegaly

Camurus' Oczyesa® Approved in the EU for Acromegaly Treatment Camurus announced the EU approval of Oczyesa®, a subcutaneous octreotide depot for acromegaly treatment, marking a significant advancement in patient care.

Camurus' Oczyesa® Approved in the EU for Acromegaly Treatment #Sweden #Lund #Camurus #Oczyesa #Acromegaly

European Medicines Agency Praises Oczyesa® for Acromegaly Treatment Advancement The CHMP recommends Oczyesa® for adult acromegaly treatment, enhancing patient care with convenient self-administration and improved outcomes.

European Medicines Agency Praises Oczyesa® for Acromegaly Treatment Advancement #Sweden #Lund #Camurus #Oczyesa #Acromegaly

Camurus Gets Positive EU Recommendation for Oczyesa® to Treat Acromegaly Patients Camurus has received a favorable opinion from the CHMP for its drug Oczyesa® to treat acromegaly, paving the way for broader patient access and innovative treatment options.

Camurus Gets Positive EU Recommendation for Oczyesa® to Treat Acromegaly Patients #Sweden #Lund #Camurus #Oczyesa #CHMP